A Phase I/II Randomized, Double-blind, Placebo-controlled Multicentre Study in Participants Aged 18 Years or Older to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19
Latest Information Update: 04 Mar 2024
At a glance
- Drugs AZD 1222 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
- Sponsors AstraZeneca
- 02 Jun 2023 Results evaluating one year safety and immunogenicity of AZD1222, published in the Vaccine.
- 01 Jan 2022 Results published in the International Journal of Infectious Diseases
- 29 Nov 2021 Status changed from active, no longer recruiting to completed.